Key result
Statin therapy increases mildly elevated liver enzymes ~41% vs placebo but spares most other adverse events.
Meta-Analysis (n=123,940)
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
May warrant liver enzyme monitoring with statins; leaves open broader safety confirmation in higher-quality studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bauersachs et al. (2026) conducted a meta-analysis in Cardiovascular disease prevention (n=123,940). Statins vs. Placebo was evaluated on Mildly elevated liver enzymes (transaminases) (RR 1.41, 95% CI 1.26-1.57). Statin therapy slightly increased the risk of mildly elevated liver enzymes compared to placebo, but showed no significant difference for 62 of 66 commonly listed adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: